Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PEPG
PEPG logo

PEPG Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy PepGen Inc (PEPG) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.790
1 Day change
5.29%
52 Week Range
7.800
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

PepGen Inc (PEPG) is not a strong buy for a beginner investor with a long-term focus at this time. While there are some positive developments, such as insider buying and a buy rating from analysts, the stock remains highly speculative with limited confidence in its platform and no near-term catalysts. The technical indicators suggest the stock is overbought, and there are no strong proprietary trading signals to support immediate action.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 83.326, signaling the stock is overbought. Moving averages are converging, and the stock is trading near its resistance level of 1.853, suggesting limited immediate upside potential.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
7

Positive Catalysts

  • Insider buying has increased significantly (294713.82% over the last month).

  • Analysts have initiated coverage with a Buy rating and a high price target of $11, indicating long-term potential.

Neutral/Negative Catalysts

  • No recent news or event-driven catalysts.

  • The stock is highly speculative with limited confidence in its platform due to past program failures.

  • Overbought technical indicators suggest potential for a pullback.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Craig-Hallum initiated coverage with a Buy rating and an $11 price target, citing long-term potential in the DM1 program. However, Wedbush lowered the price target from $5 to $4, reflecting concerns over variability in earlier data and the need for additional signals from functional assessments.

Wall Street analysts forecast PEPG stock price to rise
2 Analyst Rating
Wall Street analysts forecast PEPG stock price to rise
1 Buy
0 Hold
1 Sell
Hold
Current: 1.700
sliders
Low
3
Averages
11.5
High
20
Current: 1.700
sliders
Low
3
Averages
11.5
High
20
Craig-Hallum
Adam Vodel
initiated
$11
AI Analysis
2026-06-16
New
Reason
Craig-Hallum
Adam Vodel
Price Target
$11
AI Analysis
2026-06-16
New
initiated
Reason
As previously reported, Craig-Hallum analyst Adam Vodel initiated coverage of PepGen with a Buy rating and $11 price target. The firm views PepGen as a high-risk but highly asymmetric myotonic dystrophy recovery story, with shares appearing to reflect limited confidence in both PGN-EDODM1 and the broader EDO platform following the Duchenne program failure. While the early DM1 SAD/MAD dataset remains noisy, Craig-Hallum believes it is sufficiently encouraging to justify continued development and keep the program in the DM1 conversation. Looking ahead, the key catalyst is the 10 mg/kg FREEDOM2 cohort expected in the second half of 2026, which the firm views as the most important dataset to determine whether PGN-EDODM1 can emerge as a credible disease-modifying therapy in DM1.
Craig-Hallum
Adam Vodel
Buy
initiated
$11
2026-06-16
New
Reason
Craig-Hallum
Adam Vodel
Price Target
$11
2026-06-16
New
initiated
Buy
Reason
Craig-Hallum analyst Adam Vodel initiated coverage of PepGen with a Buy rating and $11 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for PEPG
Unlock Now

People Also Watch